Clinical Trials
38 trialsStudy of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Memorial Sloan Kettering Cancer Center
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Dana-Farber Cancer Institute
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Memorial Sloan Kettering Cancer Center
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
University of Cincinnati
I-SPY
QuantumLeap Healthcare Collaborative
DOVE
Yonsei University
BeeHive
University Health Network, Toronto
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
University of Hawaii
Superhero
Universitaire Ziekenhuizen KU Leuven
STAR
University of Oklahoma
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
M.D. Anderson Cancer Center
IMMUNOSTAR
Gruppo Oncologico Italiano di Ricerca Clinica
Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma
Chang Gung Memorial Hospital
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Beth Israel Deaconess Medical Center
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Pan-MSI-ACSE
UNICANCER
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
University of Pittsburgh
NADiR
Massachusetts General Hospital
RODEO
University College, London
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Mayo Clinic
NADIA
Grupo Español de Investigación en Cáncer de Ovario
NAIO
University of Iowa
ATOMICC
Grupo Español de Investigación en Cáncer de Ovario
DOVIPA
Hopital Foch
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
University of Pittsburgh
PREDOSTAR
Centre Leon Berard
IMPRESS-N
Oslo University Hospital
DEWI
GERCOR - Multidisciplinary Oncology Cooperative Group
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
University Health Network, Toronto
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
UNITO-001
University of Turin, Italy
MiST
University of Leicester
Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia
University of Miami
PRIME
Gruppo Oncologico del Nord-Ovest
Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Hoosier Cancer Research Network